G93 Stock Overview
A vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Jiangsu Recbio Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.99 |
| 52 Week High | HK$1.10 |
| 52 Week Low | HK$0.81 |
| Beta | -0.23 |
| 11 Month Change | 0.51% |
| 3 Month Change | 4.65% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| G93 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.6% | -0.7% | 0.2% |
| 1Y | n/a | -17.2% | 8.5% |
Return vs Industry: Insufficient data to determine how G93 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how G93 performed against the German Market.
Price Volatility
| G93 volatility | |
|---|---|
| G93 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: G93 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine G93's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 507 | Yong Liu | www.recbio.cn |
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage.
Jiangsu Recbio Technology Co., Ltd. Fundamentals Summary
| G93 fundamental statistics | |
|---|---|
| Market cap | €486.33m |
| Earnings (TTM) | -€72.19m |
| Revenue (TTM) | €5.71m |
85.1x
P/S Ratio-6.7x
P/E RatioIs G93 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G93 income statement (TTM) | |
|---|---|
| Revenue | CN¥43.40m |
| Cost of Revenue | CN¥17.09m |
| Gross Profit | CN¥26.31m |
| Other Expenses | CN¥574.86m |
| Earnings | -CN¥548.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 60.63% |
| Net Profit Margin | -1,263.92% |
| Debt/Equity Ratio | 81.5% |
How did G93 perform over the long term?
See historical performance and comparison